AstraZeneca has dropped two oncology programs from its clinical-phase pipeline. The Big Pharma has stopped work on AZD9496 in breast cancer and imaradenant in prostate cancer on safety or efficacy grounds.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,